TransCon VEGF-TKI

**TransCon VEGF-TKI** is an investigational **TransCon** sustained-release prodrug from **Ascendis Pharma** built on the company's transient conjugation platform, which is designed to release an **unmodified parent drug** over time while maintaining the parent drug's original mechanism of action. Publicly available pipeline information outside Ascendis' current website identifies this candidate as a **small-molecule VEGF receptor tyrosine kinase inhibitor** program with additional activity reported against **VEGFR1, VEGFR2, VEGFR3, PDGFR-beta, and KIT**, and at least one secondary source links the program to **axitinib** as the parent drug. Ascendis' current public pipeline no longer lists TransCon VEGF-TKI, suggesting the program is **preclinical and no longer an active disclosed priority**, with historical development described broadly in **oncology** rather than a named disease.